RT Journal Article
SR Electronic
T1 Risk mitigating behaviours in people with inflammatory joint and skin disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.05.20226662
DO 10.1101/2020.11.05.20226662
A1 Mahil, SK
A1 Yates, M
A1 Langan, SM
A1 Yiu, ZZN
A1 Tsakok, T
A1 Dand, N
A1 Mason, KJ
A1 McAteer, H
A1 Meynell, F
A1 Coker, B
A1 Vincent, A
A1 Urmston, D
A1 Vesty, A
A1 Kelly, J
A1 Lancelot, C
A1 Moorhead, L
A1 Bachelez, H
A1 Bruce, IN
A1 Capon, F
A1 Contreras, CR
A1 Cope, AP
A1 De La Cruz, C
A1 Di Meglio, P
A1 Gisondi, P
A1 Hyrich, K
A1 Jullien, D
A1 Lambert, J
A1 Waweru, H
A1 Marzo-Ortega, H
A1 McKinnes, I
A1 Naldi, L
A1 Norton, S
A1 Puig, L
A1 Sengupta, R
A1 Spuls, P
A1 Torres, T
A1 Warren, RB
A1 Weinman, J
A1 Griffiths, CM
A1 Barker, JN
A1 Brown, MA
A1 Galloway, JB
A1 Smith, CH
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/11/07/2020.11.05.20226662.abstract
AB Objectives Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse COVID-19 outcomes compared to patients receiving no systemic treatments. We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation.Methods Online surveys were completed by individuals with Rheumatic and Musculoskeletal Diseases (RMD) (UK only) or psoriasis (globally) between 4th May and 7th September 2020. We used multiple logistic regression to assess the association between treatment type and risk-mitigating behaviour, adjusting for clinical and demographic characteristics. We characterised international variation in a mixed effects model.Results Of 3,720 participants (2,869 psoriasis, 851 RMD) from 74 countries, 2,262 (60.8%) reported the most stringent risk-mitigating behaviour (classified here under the umbrella term ‘shielding’). A greater proportion of those receiving targeted therapies (biologics and JAK inhibitors) reported shielding compared to those receiving no systemic therapy (adjusted odds ratio [OR] 1.63, 95% CI 1.35-1.97) and standard systemic agents (OR 1.39, 95% CI 1.22-1.56). Shielding was associated with established risk factors for severe COVID-19 (male sex [OR 1.14, 95% CI 1.05-1.24], obesity [OR 1.38, 95% CI 1.23-1.54], comorbidity burden [OR 1.43, 95% CI 1.15-1.78]), a primary indication of RMD (OR 1.37, 95% CI 1.27-1.48) and a positive anxiety or depression screen (OR 1.57, 95% CI 1.36-1.80). Modest differences in the proportion shielding were observed across nations.Conclusions Greater risk-mitigating behaviour among people with IMIDs receiving targeted therapies may contribute to the reported lower risk of adverse COVID-19 outcomes. The behaviour variation across treatment groups, IMIDs and nations reinforces the need for clear evidence-based patient communication on risk mitigation strategies and may help inform updated public health guidelines as the pandemic continues.What is already known about this subject?At the beginning of the COVID-19 pandemic, patients with immune mediated inflammatory diseases (IMIDs) on targeted systemic immunosuppressive therapy were considered to be at higher risk of severe COVID-19. Subsequent registry data suggest that this may not the case.What does this study add?Here we characterise shielding behaviour in patients with IMIDs from a global survey. We identified that targeted systemic therapy associates with increased shielding behaviour, as do demographic risk factors for severe COVID-19 including male gender and obesity.Shielding behaviour varies across nations, albeit modestly when case-mix is taken into account.How might this impact on clinical practice or future developments?Variable shielding behaviour amongst patients with IMIDs may be an important confounder when considering differential COVID-19 risk between therapy types, so should be accounted for in analyses where possible.Competing Interest StatementProf. Cope reports grants from Eli Lilly, outside the submitted work. Dr. Vesty has nothing to disclose. Dr. Vincent has nothing to disclose. Mr. Bola Coker has nothing to disclose. Dr. Capon reports consultancy fees from AnaptysBio, grants from Boheringer-Ingelheim, outside the submitted work; . Dr De La Cruz has nothing to disclose. Dr. Griffiths reports grants and personal fees from AbbVie, grants from Amgen, grants from BMS, grants and personal fees from Janssen, grants from LEO, grants and personal fees from Novartis, grants from Pfizer, grants from Almirall, grants and personal fees from Lilly, grants and personal fees from UCB Pharma, outside the submitted work; . Dr. Contreras has nothing to disclose. Dr. JULLIEN reports personal fees and non-financial support from Abbvie, personal fees and non-financial support from Novartis, personal fees and non-financial support from Janssen-Cilag, personal fees and non-financial support from Lilly, personal fees and non-financial support from Leo-Pharma, personal fees and non-financial support from MEDAC, personal fees and non-financial support from Celgene, personal fees from Amgen, outside the submitted work; . Dr. Urmston reports grants from Almirral, grants from Abbvie, grants from Amgen, grants from Celgene, grants from Dermal Laboratories, grants from Eli Lilly, grants from Janssen, grants from LEO Pharma, grants from T and R Derma, grants from UCB, outside the submitted work;. Dr. Meynall has nothing to disclose. Dr. Bachelez reports personal fees from Abbvie, personal fees from Janssen, personal fees from LEO Pharma, personal fees from Novartis, personal fees from UCB, personal fees from Almirall, personal fees from Biocad, personal fees from Boehringer-Ingelheim, personal fees from Kyowa Kirin, personal fees from Pfizer, outside the submitted work; . Dr. McAteer reports grants from Abbvie, grants from Almirral, grants from Amgen, grants from Celgene, grants from Dermal Laboratories, grants from Eli Lilly, grants from Janssen, grants from LEO Pharma, grants from UCB, grants from T and R Derma, outside the submitted work;. Dr. Bruce reports grants from National Institute for Health Research, during the conduct of the study; grants from Genzyme Sanofi, grants and personal fees from GSK, grants and personal fees from UCB, personal fees from Eli Lilly, personal fees from Astra Zeneca, personal fees from MErck Serono, personal fees from Aurinia, personal fees from ILTOO, outside the submitted work; . Dr. Barker reports grants and personal fees from Abbvie, grants and personal fees from Novartis, grants and personal fees from Lilly, grants and personal fees from J&J, from null, during the conduct of the study; . Dr. Galloway reports personal fees from Abbvie, personal fees from Sanofi, personal fees from Novartis, personal fees from Pfizer, grants from Eli Lilly, personal fees from Janssen, personal fees from UCB, outside the submitted work; . Dr. Lambert has nothing to disclose. Prof Weinmann has presented talks for Abbvie, Abbott, Bayer, Chiesi, Boehringer Ingelheim, Roche and Merck. Prof. Hyrich reports grants from Bristol Myers Squibb, grants from Pfizer, personal fees from Abbvie, outside the submitted work; . Dr. MASON reports personal fees from LEO Pharma and Novartis, outside the submitted work. Dr. Moorhead reports personal fees from Abbvie, personal fees from Celgene, personal fees from Janssen, personal fees from LEO Pharma, personal fees from Novartis, personal fees from UCB, outside the submitted work; . Dr. Naldi has nothing to disclose. Dr. Puig reports grants and personal fees from AbbVie, grants and personal fees from Almirall, grants and personal fees from Amgen, grants and personal fees from Boehringer Ingelheim, personal fees from Bristol Myers Squibb, personal fees from Fresenius-Kabi, grants and personal fees from Janssen, grants and personal fees from Lilly, personal fees from Mylan, grants and personal fees from Novartis, personal fees from Pfizer, personal fees from Sandoz, personal fees from Sanofi, personal fees from Samsung-Bioepis, grants and personal fees from UCB, outside the submitted work; . Dr. Mahil reports grants from Abbvie, grants from Celgene, grants from Eli Lilly, grants from Janssen-Cilag, grants from Novartis, grants from Sanofi, from UCB|, outside the submitted work; . Dr. Marzo-Ortega reports grants and personal fees from Janssen, grants and personal fees from Novartis, personal fees from Abbvie, personal fees from Celgene, personal fees from Eli Lilly, personal fees from Pfizer, personal fees from Takeda, personal fees from UCB, outside the submitted work; . Prof. BROWN has nothing to disclose. Prof. McInnes reports grants from Abbvie, grants from Astra Zeneca, grants from Bristol Myers Squibb, grants from Boerhinger, grants from Celgene, grants from Roche, grants from Janssen, grants from Novartis, grants from Eli Lilly, grants from UCB, outside the submitted work; . Dr. Yates has nothing to disclose. Dr. Dand has nothing to disclose. Dr. Gisondi reports personal fees from Abbvie, Amgen, Eli Lilly, Jannsen, Novartis, Pierre Fabre, Sandoz, UCB, outside the submitted work; . Dr. Di Meglio reports grants and personal fees from UCB, personal fees from Novartis, personal fees from Janssen, outside the submitted work; . Dr Sengupta: Speaker fees, consultancy and/or grants from Abbvie, Biogen, Celgene, MSD, Novartis and UCB. Dr. Warren reports grants and personal fees from Abbvie, grants and personal fees from Celgene, grants and personal fees from Eli Lilly, grants and personal fees from Novartis, personal fees from Sanofi, grants and personal fees from UCB|, grants and personal fees from Almirall, grants and personal fees from Amgen, grants and personal fees from Janssen, grants and personal fees from Leo, grants and personal fees from Pfizer, personal fees from Arena, personal fees from Avillion, personal fees from Bristol Myers Squibb, personal fees from Boehringer Ingelheim, outside the submitted work; . Dr. Langan has nothing to disclose. Dr. Smith reports grants from Abbvie, grants from Sanofi, grants from Novartis, grants from Pfizer, outside the submitted work; . Dr. Norton has nothing to disclose. Dr Spuls is a member of the ISAC of psoprotect. Dr. Tsakok has nothing to disclose. Dr. Torres reports grants and personal fees from AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biogen, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Samsung-Bioepis, Sandoz, during the conduct of the study. Dr. Yiu has nothing to disclose. Dr Waweru is on the Board of the International Federation of Psoriasis Associations who have received grants from Abbvie, Almirall, Amgen, Bristol Meyers Squibb, Boehringer Ingelheim, Celgene, Janssen, Leo Pharma, Eli Lilly, Novartis, Sun Pharma, Pfizer, and UCB, outside the submitted work; . Funding StatementWe acknowledge financial support from the Department of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London, the NIHR Manchester Biomedical Research Centre and the Psoriasis Association. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. SKM is funded by a Medical Research Council (MRC) Clinical Academic Research Partnership award (MR/T02383X/1). ND is funded by Health Data Research UK (MR/S003126/1), which is funded by the UK MRC, Engineering and Physical Sciences Research Council; Economic and Social Research Council; Department of Health & Social Care (England); Chief Scientist Office of the Scottish Government Health and Social Care Directorates; Health and Social Care Research and Development Division (Welsh Government); Public Health Agency (Northern Ireland); British Heart Foundation; and Wellcome Trust. ZZNY is funded by a NIHR Academic Clinical Lectureship through the University of Manchester. CEMG is a NIHR Emeritus Senior Investigator and is funded in part by the MRC (MR/101 1808/1). CEMG and RBW are in part supported by the NIHR Manchester Biomedical Research Centre. SML is supported by a Wellcome senior research fellowship in clinical science (205039/Z/16/Z). SML is also supported by Health Data Research UK (grant no. LOND1), which is funded by the UK MRC, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research approved by KCL research ethics committee (REC ref 20/YH/0135)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary level data available on reasonable request.